Stryker CMR Surgical Investment: $400M Robotics Bet
Stryker will invest about $400M in CMR Surgical, sell Versius in the US and hold an option to buy the rest. What the alliance covers and what is undisclosed.
Philips Lumify Ultrasound FDA Safety Alert: What to Know
Philips Lumify ultrasound FDA safety alert: four deaths and eight serious injuries reported over registration and USB faults. Affected versions and user advice.
Trace Medical LiViliti Acquisition: CPAP Hygiene Deal
Trace Medical LiViliti acquisition: majority stake in the Paptizer 360 maker after its April 2026 FDA 510(k) clearance. Terms undisclosed. What is known.
Zydus Saroglitazar Phase 3 Trial: New PBC Subgroup Data
Zydus saroglitazar Phase 3 trial: post hoc EPICS-III data show 60.7% vs 0% (US) and 55.1% vs 13.5% (non-US) response in PBC. Small groups; FDA review continues.
Lunit Discovery Life Sciences Partnership: AI Pathology
Lunit Discovery Life Sciences partnership: SCOPE AI will run inside Discovery’s tissue biomarker workflows for biopharma. What is known and what is not.
FILKRI Biosimilar US Launch: Accord Adds Short-Acting G-CSF
FILKRI biosimilar US launch: Accord BioPharma debuts filgrastim-laha, a Neupogen biosimilar, in two prefilled syringe sizes with permanent Q-code Q5172.
MT027 CAR-T Therapy FDA Clearance: Phase 2 Brain Trial
MT027 CAR-T therapy FDA clearance: T-MAXIMUM can start a Phase 2 study in lung and breast cancer brain metastases. What the data show and what is missing.
Bausch Lomb CEO Resignation 2026: Saunders Out, Appio In
Bausch Lomb CEO resignation 2026: Brent Saunders leaves by mutual decision, Thomas Appio is interim CEO, and Q3 results are due 28 October. What we know.
Merck Diabetic Macular Edema Trial: Goal Met, Safety Flags
Merck diabetic macular edema trial: remigromig matched ranibizumab on vision in BRUNELLO, but PDR-related events were about 7x higher. What we know so far.
STERIS Xodus Medical Acquisition: $2.1B Deal Explained
STERIS Xodus Medical acquisition: $2.1B for the Pink Pad maker, about 8.6x projected revenue, debt-funded, closing by year-end. Terms and open questions.